MedElevator
Войти в исследования European heart journal. Quality of care & clinical outcomes · 2026
First systematic screening of cardiac amyloidosis in the elderly: findings and cost-effectiveness profile.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ferrari Chen Yu Fu, Castiglione Vincenzo, Orsino Maria Francesca, Mori Francesco, Passino Claudio, Piepoli Massimo, Emdin Michele, Vergaro Giuseppe, Aimo Alberto
Аннотация
AIMS: Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA) is increasingly recognized in older adults. Nonetheless, its true prevalence in unselected subjects is unclear. We performed a systematic screening in 1000 individuals aged 65-90 years to identify CA and assess the clinical and economic impact of diagnosing both CA and incidental findings.
METHODS AND RESULTS: All participants underwent a cardiology visit, electrocardiogram, echocardiogram, and measurement of cardiac biomarkers. Patients with any red flag proceeded to bone scintigraphy and monoclonal protein testing. We catalogued incidental cardiac or renal abnormalities, referred individuals for further evaluation, and estimated total screening costs. We then incorporated tafamidis therapy for the newly diagnosed patients with CA and conducted two cost-effectiveness analyses: one excluding quality-adjusted life years (QALYs) from incidental diagnoses and another one including them. Four new cases of ATTRwt-CA were diagnosed (0.46%). Additional findings included moderate-to-severe valvular disease, conduction abnormalities requiring device implantation, and previously unknown Stage 3-5 chronic kidney disease in 15.6% of participants. The total non-drug screening cost was around €252 000, while tafamidis (5 years, four patients) added €1 080 000. Excluding incidental benefits, the incremental cost-effectiveness ratio (ICER) was around €94 000 per QALY. With an estimated 15-20 extra QALYs from incidental findings, the ICER fell to €39 000-€46 000 per QALY.
CONCLUSION: A structured screening programme for CA in elderly subjects can uncover important comorbidities but remains expensive, with an incremental cost of approximately €39 000-€94 000 per QALY; the overall value of such a strategy will therefore depend on tafamidis pricing and the willingness-to-pay threshold adopted by individual health systems.
METHODS AND RESULTS: All participants underwent a cardiology visit, electrocardiogram, echocardiogram, and measurement of cardiac biomarkers. Patients with any red flag proceeded to bone scintigraphy and monoclonal protein testing. We catalogued incidental cardiac or renal abnormalities, referred individuals for further evaluation, and estimated total screening costs. We then incorporated tafamidis therapy for the newly diagnosed patients with CA and conducted two cost-effectiveness analyses: one excluding quality-adjusted life years (QALYs) from incidental diagnoses and another one including them. Four new cases of ATTRwt-CA were diagnosed (0.46%). Additional findings included moderate-to-severe valvular disease, conduction abnormalities requiring device implantation, and previously unknown Stage 3-5 chronic kidney disease in 15.6% of participants. The total non-drug screening cost was around €252 000, while tafamidis (5 years, four patients) added €1 080 000. Excluding incidental benefits, the incremental cost-effectiveness ratio (ICER) was around €94 000 per QALY. With an estimated 15-20 extra QALYs from incidental findings, the ICER fell to €39 000-€46 000 per QALY.
CONCLUSION: A structured screening programme for CA in elderly subjects can uncover important comorbidities but remains expensive, with an incremental cost of approximately €39 000-€94 000 per QALY; the overall value of such a strategy will therefore depend on tafamidis pricing and the willingness-to-pay threshold adopted by individual health systems.